Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer
about
sameAs
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells.Tumour suppressor genes in chemotherapeutic drug response.Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patientsMethylation of tumor suppressor genes in ovarian cancer.Consortium analysis of 7 candidate SNPs for ovarian cancer.Role of p53 and Rb in ovarian cancer.Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk.Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGF‑β1-mediated cell cycle arrest.CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.
P2860
Q27851620-E8D20CB0-90BA-40B2-B763-0C316026F301Q34666213-4F4ACB07-BE7C-49BE-B576-97A30A5EA7FBQ34683406-6F6F37E6-41DB-40BE-B6E6-6A102B6C9FE8Q36083098-1679279C-E5FC-4984-9DEB-7BDCA68C8B4EQ36286635-E71B9435-4D1D-4C5A-AC9E-1DA650BAFFBFQ36386613-53185079-A069-4BF3-AA33-FB12C0DC6CE1Q37155532-487548FA-E530-464A-9169-B335EDCA7C75Q37188853-FAE598A3-3D8F-42AC-B658-AAF62AAE4DD2Q37344880-C9A1BEF5-988C-4393-A88A-3D7B53E56317Q38099749-DE44DE54-146B-43E4-824B-B324D424E046Q42378301-0B0C632D-8C69-481A-9A90-5883CA4CAE23Q52592862-1D3FAB43-3E01-4274-811C-F62165BD17FC
P2860
Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@ast
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@en
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@nl
type
label
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@ast
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@en
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@nl
prefLabel
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@ast
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@en
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@nl
P2093
P2860
P356
P1476
Inactivation of p16/CDKN2 and ...... chemotherapy in ovarian cancer
@en
P2093
Ichiro Nagata
Kazuhiko Uchida
Kazuya Kudoh
Masanao Miwa
Misako Hirai
Sadao Yoshida
Yoshihiro Kikuchi
Yoshihito Ichikawa
P2860
P304
P356
10.1002/IJC.10331
P407
P577
2002-06-01T00:00:00Z